About Citius Pharmaceuticals (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book1.13
Return on Equity-62.42%
Return on Assets-47.82%
Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions
What is Citius Pharmaceuticals' stock symbol?
Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."
When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?
Citius Pharmaceuticals shares reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.
Who are some of Citius Pharmaceuticals' key competitors?
Some companies that are related to Citius Pharmaceuticals include Arcturus Therapeutics (ARCT), Aptevo Therapeutics (APVO), Catabasis Pharmaceuticals (CATB), Caladrius Biosciences (CLBS), PLx Pharma (PLXP), Opiant Pharmaceuticals (OPNT), pSivida (PSDV), Novus Therapeutics (NVUS), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Pain Therapeutics (PTIE), Immutep (IMMP), VIVUS (VVUS), Proteon Therapeutics (PRTO), IntelGenx Technologies (IGXT), Celsion (CLSN), Acerus Pharmaceuti (TRLPF) and ReNeuron (RNUGF).
Who are Citius Pharmaceuticals' key executives?
Citius Pharmaceuticals' management team includes the folowing people:
- Leonard L. Mazur, Executive Chairman of the Board, Secretary (Age 71)
- Myron Z. Holubiak, President, Chief Executive Officer, Director (Age 69)
- Jaime Bartushak, Chief Financial Officer, Principal Financial Officer
- Suren G. Dutia, Director (Age 72)
- Eugene Holuka, Director (Age 57)
- William J. Kane, Director (Age 72)
- Howard Safir, Director (Age 75)
- Carol A. Webb, Director (Age 69)
Has Citius Pharmaceuticals been receiving favorable news coverage?
Headlines about CTXR stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Citius Pharmaceuticals earned a news impact score of 0.17 on Accern's scale. They also gave media stories about the company an impact score of 46.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Citius Pharmaceuticals' major shareholders?
Which institutional investors are buying Citius Pharmaceuticals stock?
How do I buy shares of Citius Pharmaceuticals?
Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Citius Pharmaceuticals' stock price today?
One share of CTXR stock can currently be purchased for approximately $3.01.
How big of a company is Citius Pharmaceuticals?
Citius Pharmaceuticals has a market capitalization of $30.42 million. Citius Pharmaceuticals employs 7 workers across the globe.
How can I contact Citius Pharmaceuticals?
Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.
MarketBeat Community Rating for Citius Pharmaceuticals (CTXR)MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Citius Pharmaceuticals (NASDAQ:CTXR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Citius Pharmaceuticals (NASDAQ:CTXR)
No earnings announcements for this company have been tracked by MarketBeat.com
Citius Pharmaceuticals (NASDAQ:CTXR) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.25 EPS
Dividend History for Citius Pharmaceuticals (NASDAQ:CTXR)
No dividend announcements for this company have been tracked by MarketBeat.com
Citius Pharmaceuticals (NASDAQ CTXR) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 2.38%
Citius Pharmaceuticals (NASDAQ CTXR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/24/2017||Leonard L Mazur||Insider||Buy||11,000||$2.68||$29,480.00||3,337,730|| |
|8/8/2017||Leonard L Mazur||Insider||Buy||421,400||$4.13||$1,740,382.00||1,779,663|| |
Citius Pharmaceuticals (NASDAQ CTXR) News Headlines
Citius Pharmaceuticals (NASDAQ:CTXR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Citius Pharmaceuticals (NASDAQ CTXR) Stock Chart for Thursday, March, 22, 2018